Adma Biologics Inc (NASDAQ: ADMA) is -7.64% lower on its value in year-to-date trading and has touched a low of $5.02 and a high of $23.64 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The ADMA stock was last observed hovering at around $15.88 in the last trading session, with the day’s loss setting it -0.04%.
Currently trading at $15.84, the stock is -3.38% and -10.13% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.32 million and changing -0.25% at the moment leaves the stock 2.84% off its SMA200. ADMA registered 202.29% gain for a year compared to 6-month gain of -3.71%. The firm has a 50-day simple moving average (SMA 50) of $17.7455 and a 200-day simple moving average (SMA200) of $15.355425.
The stock witnessed a -3.94% loss in the last 1 month and extending the period to 3 months gives it a -29.97%, and is -6.11% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 3.91% over the week and 4.23% over the month.
Adma Biologics Inc (ADMA) has around 624 employees, a market worth around $3.74B and $382.81M in sales. Current P/E ratio is 57.33 and Fwd P/E is 22.52. Profit margin for the company is 17.80%. Distance from 52-week low is 215.54% and -32.99% from its 52-week high. The company has generated returns on investments over the last 12 months (19.92%).
with sales reaching $112.77M over the same period.The EPS is expected to grow by 494.87% this year, but quarterly earnings will post 63.61% year-over-year. Quarterly sales are estimated to grow 52.59% in year-over-year returns.
The shares outstanding are 236.38M, and float is at 227.35M with Short Float at 5.80%.
The top institutional shareholder in the company is BLACKROCK INC. with over 18.64 million shares valued at $208.45 million. The investor’s holdings represent 8.1462 of the ADMA Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 14.52 million shares valued at $162.3 million to account for 6.3426 of the shares outstanding. The other top investors are INVESCO LTD. which holds 13.17 million shares representing 5.7546 and valued at over $147.25 million, while NUVEEN ASSET MANAGEMENT, LLC holds 3.8996 of the shares totaling 8.93 million with a market value of $99.78 million.
Adma Biologics Inc (ADMA) Insider Activity
The most recent transaction is an insider sale by Tade Brad L., the company’s CFO and Treasurer. SEC filings show that Tade Brad L. sold 15,000 shares of the company’s common stock on Nov 22 ’24 at a price of $21.15 per share for a total of $0.32 million. Following the sale, the insider now owns 0.2 million shares.
Adma Biologics Inc disclosed in a document filed with the SEC on Nov 22 ’24 that Grossman Adam S (President and CEO) sold a total of 48,967 shares of the company’s common stock. The trade occurred on Nov 22 ’24 and was made at $21.10 per share for $1.03 million. Following the transaction, the insider now directly holds 1.99 million shares of the ADMA stock.
Still, SEC filings show that on Nov 22 ’24, Grossman Adam S (Director and Officer) Proposed Sale 48,967 shares at an average price of $21.30 for $1.04 million. The insider now directly holds shares of Adma Biologics Inc (ADMA).
